Perrigo Prioritizes Innovating First After Following OTC Brands To Market
Perrigo’s "national brand better" approach includes adding "better" value to generic equivalents that branded aren't offering, says President and CEO Murray Kessler. Prevacid 24 HR acquisition puts Perrigo at top of 15-mg lansoprazole PPI brand sales as well as in the generics market.
You may also be interested in...
Perrigo Reaches Year Anniversary For First OTC Brand Switch With Sixth Packaging Approval
Latest FDA approval for mometasone furoate, 50-mcg metered spray, is for three 144-spray containers. Nasonex 24HR Allergy is Perrigo’s first OTC switch of national brand and first mometasone furoate offered nonprescription in US.
Perrigo Has First US Approval For OTC Omeprazole Mini-Capsule
Capsule is 70% smaller than tablets of omeprazole currently available in Prilosec OTC and generic equivalents, including formulations Perrigo provides for its private label and store brand customers.
Perrigo Adds University Research To Tool Box With Deals And Pipeline For Self-Care Market Growth
“Formal partnership” connects Michigan State's clinical and research expertise with Perrigo's product innovation, manufacturing scale and retail distribution network, Despite breadth and depth of Perrigo’s product lineup, it expects another $1b annually could come from segments where it has no or little market share.